Table 1. NCI Common Toxicity Criteria Version 3.0 Dermatological Adverse Events Relevant to EGFR Inhibition.

Grade
Symptom	1	2	3	4	5
Dry skin	Asymptomatic	Symptomatic, not interfering with ADL	Interfering with ADL
Hair loss/Alopecia (Scalp or Body)	Thinning or patchy	Complete
Hyperpigmentation	Slight or Localized	Marked or Generalized
Rash: acne/acneiform	Intervention not indicated	Intervention indicated	Associated with pain, disfigurement, ulceration, or desquamation		Death
Pruritis/itching	Mild or Localized	Intense or widespread	Intense or widespread and interfering with ADL
Nail changes	Discoloration; ridging (koilonychia); pitting	Partial or complete loss of nail(s); pain in nailbed(s)	Interfering with ADL